Analysis for CL

📈 Growth & Financial Trajectory

Over 8 quarters, revenues rose from about $4.50B in 2024 Q3 to $5.36B in 2026 Q2, up ~19%. Net income attributable to parent drifted from $792M to $693M, with periodic fluctuations but generally stable profitability. The trajectory signals durable demand and pricing power, though earnings progress isn’t strictly linear due to input costs and currency effects.

💰 Margins & Cash Flow

Gross margin stayed robust around 60%–62% (peaking near 68% in 2024 Q3). Operating margins remained in the high teens, supporting positive cash generation. Net cash from operating activities ranged roughly $0.6B–$1.0B per quarter; investing typically negative as the company funds growth, with financing varying.

🛡️ Balance Sheet & Liquidity

Assets run about $16.0B–$16.8B against liabilities near $15.9B–$17.7B. Long-term debt sits around $7.0B–$10.0B; equity is modest, yielding a lean balance sheet by turnover. Current ratio hovers near 1.0–1.3, providing modest liquidity resilience.

⚠️ Key Drivers & Risks

• Drivers: steady demand for oral care, strong brand pricing power.
• Risks: commodity/input cost pressure, FX volatility and valuation sensitivity to margin shocks.